Retatrutide diarrhoea — how long does it last, and what can you do about it? Retatrutide (LY3437943) is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, currently in phase 3 clinical trials. Like other incretin-based therapies, it commonly causes gastrointestinal side effects, with diarrhoea among the most frequently reported. Understanding the typical duration, triggers, and management strategies can help people participating in trials make informed decisions and know when to seek medical advice.

Why Retatrutide Causes Diarrhoea in Some People

Retatrutide causes diarrhoea through multifactorial mechanisms likely involving delayed gastric emptying, altered intestinal fluid secretion, and CNS effects on gut function, consistent with the broader GLP-1 receptor agonist drug class.

Retatrutide (development code LY3437943) is an investigational triple receptor agonist that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor activity distinguishes it from earlier agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP agonist). Phase 2 trial data published in the New England Journal of Medicine (2023) demonstrated substantial weight loss with retatrutide, but also confirmed that gastrointestinal side effects — including diarrhoea — were among the most commonly reported adverse events.

The precise mechanisms by which GLP-1 receptor agonists cause diarrhoea are not fully established. They are likely multifactorial and may involve delayed gastric emptying, altered intestinal fluid secretion, and central nervous system effects on gut function. Whether the additional glucagon receptor activity in retatrutide meaningfully alters the gastrointestinal side-effect profile compared with single or dual agonists has not been established in head-to-head studies, and such comparisons should be interpreted with caution.

What is clear from published phase 2 data is that diarrhoea is among the most commonly reported adverse effects, particularly during the early weeks of treatment and following each dose increase. Individual susceptibility varies, and factors such as pre-existing irritable bowel syndrome, dietary habits, and concomitant medications may influence severity.

Retatrutide has not yet received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and its full gastrointestinal side-effect profile continues to be characterised through ongoing phase 3 trials.

How Long Diarrhoea Typically Lasts on Retatrutide

Diarrhoea is most pronounced during dose escalation and may begin to settle within one to two weeks of reaching a stable dose, though this estimate is based on class experience rather than retatrutide-specific data.

Retatrutide-specific data on the precise duration of diarrhoea episodes are limited; the available information comes primarily from the phase 2 randomised controlled trial (NEJM, 2023) and from broader experience with the GLP-1 receptor agonist drug class. Based on this combined evidence, gastrointestinal side effects tend to follow a broadly predictable temporal pattern.

For most participants in clinical trials, diarrhoea is most pronounced during the dose-escalation phase of treatment. Individual episodes often improve as the gastrointestinal tract adapts to each new dose level, a pattern consistent with that observed with other incretin-based therapies such as semaglutide and liraglutide. Once a stable maintenance dose is reached, many people experience a meaningful reduction in bowel symptoms. As a general guide based on class experience, symptoms following a dose increase often begin to settle within one to two weeks, though this timeframe is not derived from retatrutide-specific data and individual experience will vary.

In line with NHS guidance on diarrhoea in adults, symptoms persisting beyond seven days warrant review by a GP or, for trial participants, the supervising trial team.

Factors that may prolong or worsen symptoms include:

• Rapid dose escalation beyond what the individual gut can tolerate

• High-fat, high-sugar, or heavily processed dietary intake

• Concurrent use of medications that can independently cause loose stools, such as metformin, magnesium-containing preparations, or orlistat — a clinician should review the full medication list if diarrhoea is persistent

• Underlying gastrointestinal conditions such as inflammatory bowel disease or coeliac disease

Real-world duration of symptoms may differ from controlled trial settings. Patients participating in trials or accessing retatrutide through research programmes should discuss their specific symptom timeline with their supervising clinician.

Managing Diarrhoea During Retatrutide Treatment

Management begins with dietary modifications — smaller meals, avoiding high-fat foods, and staying hydrated with oral rehydration salts — with short-term loperamide as an option for mild to moderate symptoms.

Effective management of diarrhoea during retatrutide treatment begins with dietary and lifestyle modifications, which are generally the first-line approach for gastrointestinal side effects associated with incretin-based therapies.

Practical dietary measures include:

• Eating smaller, more frequent meals rather than large portions

• Avoiding high-fat, fried, or heavily processed foods, which can worsen gut transit

• Reducing intake of alcohol, caffeine, and artificial sweeteners (particularly sorbitol and mannitol), all of which can exacerbate loose stools

• Temporarily reducing insoluble fibre (found in wholegrain cereals, raw vegetables, and bran) if these appear to worsen symptoms

• Staying well hydrated — oral rehydration salts (ORS), available from pharmacies, are recommended to replace fluid and electrolytes lost during diarrhoea; people with diabetes should be aware that some ORS products contain sugar and should choose accordingly or seek pharmacist advice

Over-the-counter antidiarrhoeal medicines:

Loperamide may provide short-term symptomatic relief for mild to moderate diarrhoea by reducing intestinal motility and increasing fluid absorption. It should be used in accordance with the BNF and product labelling. Important UK cautions include: do not use if there is blood or mucus in the stool, high fever, or suspected antibiotic-associated (including Clostridioides difficile) colitis. If symptoms have not improved within 48 hours, seek advice from a pharmacist, GP, or trial team before continuing. Loperamide is not suitable for prolonged unsupervised use.

Dose adjustment:

In clinical trial settings, dose reduction or a temporary dose pause has been used when gastrointestinal side effects become intolerable, allowing the gut to recover before re-escalating more gradually. Any adjustment to dosing must be made in consultation with the supervising clinician or trial team — patients should not alter their dose independently.

If severe abdominal pain develops — particularly persistent epigastric pain — no further doses should be taken and urgent medical or trial team review should be sought (see the section below on when to seek medical advice).

Maintaining a symptom diary — noting frequency, stool consistency, timing relative to doses, and any dietary triggers — can help clinicians tailor management effectively.

When to Seek Medical Advice About Your Symptoms

Seek prompt medical advice if diarrhoea lasts more than seven days, blood or mucus appears in the stool, or symptoms of dehydration, pancreatitis, or gallbladder disease develop.

Mild, transient diarrhoea is a recognised and generally manageable side effect of retatrutide. However, there are specific circumstances in which prompt medical attention is required.

Contact your GP, trial team, or seek urgent medical care if you experience any of the following:

• Diarrhoea lasting more than seven days without improvement

• Blood or mucus in the stool, which may indicate colitis or another serious gastrointestinal condition

• Signs of dehydration, including dizziness, reduced urine output, dry mouth, or confusion — particularly in older adults or those with diabetes; call 999 if there is severe confusion or collapse

• Persistent severe pain in the upper abdomen (epigastrium) or pain radiating through to the back, with or without vomiting — this may suggest acute pancreatitis, which has been reported with GLP-1 receptor agonist therapies; if pancreatitis is suspected, do not take any further doses and seek urgent medical assessment immediately

• Pain in the upper right abdomen, or yellowing of the skin or whites of the eyes (jaundice) — these may indicate gallbladder disease, a risk associated with rapid weight loss and GLP-1 receptor agonist use

• Fever accompanying diarrhoea, which may suggest an infective cause requiring separate investigation

• Significant unintentional weight loss beyond what is expected from the treatment

For people with type 2 diabetes: persistent diarrhoea can reduce carbohydrate absorption and increase the risk of hypoglycaemia, particularly if insulin or sulphonylureas are co-prescribed. Increase blood glucose monitoring during episodes of significant diarrhoea and seek advice from your diabetes team if needed.

UK healthcare contacts: contact your GP surgery, call NHS 111, or — in emergencies — attend an A&E department or call 999. Those enrolled in clinical trials should contact their trial coordinator in the first instance, as adverse event reporting is a critical component of ongoing safety monitoring.

Reporting side effects: suspected side effects from medicines — including those received as part of a clinical trial — can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Trial participants should also report via their trial team.

What Current Evidence and Clinical Trials Tell Us

Phase 2 trial data (NEJM, 2023) confirmed diarrhoea as a common, mostly mild-to-moderate side effect of retatrutide; phase 3 trials are ongoing and the drug remains unlicensed in the UK.

Retatrutide (LY3437943) is being developed by Eli Lilly and Company. The most significant published evidence to date comes from a phase 2 randomised controlled trial published in the New England Journal of Medicine in 2023, which evaluated retatrutide across multiple doses in adults with obesity. The trial reported substantial weight reduction — approximately 24% of body weight at the highest dose over 48 weeks — and confirmed that gastrointestinal adverse events were the most frequently reported side effects.

In that trial, diarrhoea was reported in a meaningful proportion of participants, with rates generally higher at elevated doses and during escalation periods. The majority of gastrointestinal events were classified as mild to moderate in severity, and most resolved without requiring permanent discontinuation of the drug. Serious gastrointestinal adverse events were uncommon but did occur, reinforcing the importance of clinical monitoring. These figures should be interpreted in the context of a controlled trial population; rates and severity in broader clinical practice may differ.

Phase 3 trials are currently underway (see ClinicalTrials.gov for current listings). These larger studies will provide more robust data on the long-term gastrointestinal tolerability of retatrutide across diverse populations, including those with type 2 diabetes and cardiovascular disease. Until these trials are complete and regulatory submissions are made to bodies such as the MHRA or EMA, retatrutide remains an investigational agent and is not available as a licensed treatment in the UK.

There is currently no NICE technology appraisal guidance on retatrutide, as the drug has not yet completed the regulatory and appraisal process. Clinicians and patients should rely on trial-specific protocols and peer-reviewed literature for evidence-based decision-making. Updated guidance from NICE and the MHRA will depend on the outcomes of ongoing regulatory review.

Frequently Asked Questions